Portal de Periódicos da CAPES

Lyophilized liposome encapsulated hemoglobin

1994; Lippincott Williams & Wilkins; Volume: 22; Issue: 3 Linguagem: Inglês

10.1097/00003246-199403000-00019

1530-0293

Reuven Rabinovici, Alan S. Rudolph, Jerome Vernick, Giora Feuerstein,

Erythrocyte Function and Pathophysiology

Objective To characterize the hemodynamic, biochemical, and hematologic responses to the administration of the oxygen-carrying fluid lyophilized liposome-encapsulated hemoglobin in the conscious, normovolemic rat. Design Prospective, randomized trial. Setting Animal laboratory, Jefferson Medical College. Subjects Eighty-four male Sprague-Dawley rats. Interventions Catheters were introduced into the right atrium (through the jugular vein) and both femoral arteries of test animals, and a thermistor was placed in the ascending aorta through the left common carotid artery for infusion of lyophilized liposome-encapsulated hemoglobin, blood collection, and blood pressure (BP) and cardiac output determinations. Measurements and Main Results Lyophilized liposome-encapsulated hemoglobin (n = 8) infusion (1 mL/min iv) at 1 or 6 mL/kg (10% of estimated blood volume) had no detectable effect on BP, cardiac output, total peripheral resistance, and heart rate during the 5-hr observation period. The infusion also had no effect on hematocrit, leukocyte count, and serum tumor necrosis factor-α concentrations. Survival at 7 days was 100% (n = 20). Lyophilized liposomeencapsulated hemoglobin caused transient (2-hr) thrombocytopenia (-24 ± 9% vs. a Ringer's lactate control group, p < .01), and marginally increased serum thromboxane B2 concentrations (14.6 ± 6 pg/100 μL, p < .01). Conclusions These data suggest that lyophilized liposome-encapsulated hemoglobin can be safely administered to conscious rats, supporting the development of this substance as a potential blood substitute. (Crit Care Med 1994; 22:480–485)